Pharmacological Assessment of Tris(2-aminoethyl)amine Derivative in Animal Models of Anxiety and Depression

Abstract

Anxiety and depression are among the most prevalent mental health disorders, affecting a vast portion of the population. Despite the well-established efficacy of first-line anxiolytic and antidepressant treatments, their significant side effects often drive individuals to seek alternative therapies. Trisamine-based drugs have drawn interest in the modern age because of their potency, efficacy, broad pharmacological activity, and decreased adverse effects. They are a safer, more effective, and more affordable option for treating mental health issues because of their promising therapeutic profile. Trisamine derivatives' neuropharmacological potential was assessed in this study, with a focus on their sedative, anxiolytic, and antidepressant properties. The chosen compound was screened using a variety of behavioral models, and the results were significant. Although Compound C-1 showed a dose dependant sedative activity in open field test, however it demonstrated highly significant (***P< 0.001) anxiolytic effects in behavioral assessments. Although compound C-1 proved ineffective against antidepressant action at low dosesin the forced swimming test (FST). The selected compounds exhibited strong neuropharmacological effects.